U.S. patent application number 15/633543 was filed with the patent office on 2017-12-14 for skin tightening lotion.
The applicant listed for this patent is Ashley Diana Black International Holdings, LLC. Invention is credited to Ashley D. Black.
Application Number | 20170354590 15/633543 |
Document ID | / |
Family ID | 59561165 |
Filed Date | 2017-12-14 |
United States Patent
Application |
20170354590 |
Kind Code |
A1 |
Black; Ashley D. |
December 14, 2017 |
SKIN TIGHTENING LOTION
Abstract
Compositions for tightening the skin and reducing muscle pain,
bruising, and swelling in skin and methods of forming such
compositions.
Inventors: |
Black; Ashley D.; (Pearland,
TX) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Ashley Diana Black International Holdings, LLC |
Pearland |
TX |
US |
|
|
Family ID: |
59561165 |
Appl. No.: |
15/633543 |
Filed: |
June 26, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15181151 |
Jun 13, 2016 |
9730972 |
|
|
15633543 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 8/362 20130101;
A61K 8/37 20130101; A61K 2300/00 20130101; A61K 2300/00 20130101;
A61K 2300/00 20130101; A61K 36/899 20130101; A61Q 19/00 20130101;
A61K 8/86 20130101; A61K 8/11 20130101; A61K 8/97 20130101; A61K
8/345 20130101; A61K 8/0216 20130101; A61K 36/28 20130101; A61K
2800/31 20130101; A61K 8/342 20130101; A61K 8/375 20130101; A61Q
17/04 20130101; A61Q 19/007 20130101; A61K 36/899 20130101; A61K
2800/5922 20130101; A61K 8/678 20130101; A61K 8/9789 20170801; A61K
36/886 20130101; A61K 36/28 20130101; A61K 8/9794 20170801; A61K
2800/48 20130101; A61K 36/886 20130101; A61K 8/8182 20130101 |
International
Class: |
A61K 8/97 20060101
A61K008/97; A61K 8/362 20060101 A61K008/362; A61K 8/34 20060101
A61K008/34; A61K 8/02 20060101 A61K008/02; A61K 8/11 20060101
A61K008/11; A61K 8/37 20060101 A61K008/37; A61Q 19/00 20060101
A61Q019/00; A61K 8/67 20060101 A61K008/67; A61Q 17/04 20060101
A61Q017/04 |
Claims
1. A composition comprising: Aloe barbadensis leaf juice,
caprylic/capric triglyceride, Arnica montana flower extract, oat
kernel extract, tocopheryl acetate, fragrance, and citric acid,
wherein the Aloe barbadensis leaf juice is from about 5.0% to about
10.0, the caprylic/capric triglyceride is from about 1.0% to about
4.0%, the Arnica montana flower extract is from about 0.1% to about
0.9%, the oat kernel extract is from about 0.1% to about 0.9%, the
tocopheryl acetate is from about 0.1% to about 0.9, the fragrance
is from about 0.01% to about 0.09%, and the citric acid is from
about 0.01% to about 0.09% of the total weight by volume of the
composition.
2. The composition of claim 1, further comprising water, wherein
the water is 55.0% to 85.0% of the total weight by volume of the
composition.
3. The composition of claim 1, further comprising isopropyl
myristate, wherein the isopropyl myristate is 1.0% to 4.0% of the
total weight by volume of the composition.
4. The composition of claim 1, further comprising glycerin, wherein
the glycerin is 1.0% to 4.0% of the total weight by volume of the
composition.
5. The composition of claim 1, further comprising caprylyl glycol,
wherein the caprylyl glycol is 0.1% to 0.9% of the total weight by
volume of the composition.
6. The composition according to claim 1, wherein the composition is
encapsulated.
7. The composition of claim 1, further comprising an
antioxidant.
8. The composition of claim 1, further comprising a UV adsorption
agent.
9. The composition of claim 1, further comprising an antibacterial
agent.
10. The composition of claim 1, further comprising an antifungal
agent.
11. The composition of claim 1, further comprising a moisturizing
agent.
12. The composition of claim 1, further comprising an
emulsifier.
13. The composition of claim 1, further comprising a thickening
agent.
14. The composition of claim 1, further comprising a structuring
agent.
15. The composition of claim 1, further comprising a pharmaceutical
ingredient.
16. The composition of claim 1, wherein the composition is in the
form of an emulsion.
17. The composition of claim 1, wherein the composition is in the
form of a cream.
18. The composition of claim 1, wherein the composition is in the
form of a lotion.
19. The composition of claim 1, wherein the composition is in the
form of a gel.
20. The composition of claim 1, wherein the composition is in the
form of an anhydrous base.
Description
RELATED APPLICATIONS
[0001] This Application is a continuation of U.S. Non-Provisional
application Ser. No. 15/181,151, filed Jun. 13, 2016, entitled SKIN
TIGHTENING LOTION, the contents of which is hereby incorporated by
reference in its entirety.
FIELD OF THE INVENTION
[0002] The principles of the present invention relate generally to
compositions and methods of forming such compositions for topical
application to the skin, where the compositions include various
plant extracts and the use of such compositions provide benefits to
the skin, in particular, for application post-treatment of fascia
tissue with a fascia tissue treatment device to reduce swelling,
bruising, and muscle pain.
BACKGROUND OF THE INVENTION
[0003] Fascia is a layer of fibrous connective tissue beneath the
skin that attaches, stabilizes, encloses, separates muscles and
other internal organs, and performs other functions. The tissue
allows for proper functioning of muscles with respect to one
another and nerve communications, among other dynamic operations.
When fascia tissue becomes damaged by injury, tissue knots, or
other medical reasons, it can take time to correct itself.
Alternatively, fascia distortions of all types can be repaired by
direct manipulation, such as fascial release and/or therapy, to
allow for proper functioning of the tissue and allow the underlying
muscle as well as other bodily functions to properly operate. In
some cases, damaged fascia can be repaired without much difficulty,
while in other cases, restoring fascia to its proper form can take
considerably more effort. For instance, treatment with a fascia
therapy device can cause bruising, swelling, and localized muscle
pain. Fascia, when properly treated, can considerably reduce the
dimples in skin caused by cellulite, as well as many other cosmetic
benefits to the skin and shape of the body.
[0004] It is common after fascial release for skin or tissue to
bruise or appear to bruise as a result of blood flow. Contusion can
be unappealing and long lasting. Pain and swelling may be
associated with bruising or the appearance of bruising, and may
cause discomfort. In a bruise or appearance of bruising, distress
to tissue may cause capillaries to break under the skin, allowing
blood to escape and become visible. As time progresses, blood may
seep into the surrounding tissues, causing the bruise to darken and
spread. Nerve endings within the affected tissue detect the
increased pressure which, depending upon the severity and location,
may be perceived as pain or pressure.
[0005] Means for treating light bruises or their appearance are
limited and may include rest, ice, compression, elevation,
painkillers and, later in recovery, light stretching exercises.
Immediate application of ice while elevating the bruised area may
help reduce swelling. Although, the need remains for additional
approaches.
[0006] Moreover, there is active interest in the cosmetics industry
in developing products that may be applied topically to the skin to
counteract adverse changes in the skin, such as loosening of skin
and bruising. As subcutaneously fat loss occurs, the connective
tissue, fibers, and other structures in the dermal and sub-dermal
layers can remain, leaving the skin loose. As a result, cosmetic
products that reverse or forestall such changes are increasingly in
demand as consumers continually seek to improve the appearance of
excess skin, muscle pain, bruising, and swelling resulting from
treatment with, for example, a fascia tissue device.
BRIEF SUMMARY OF THE INVENTION
[0007] The use of a fascia tissue treatment device to treat fascia
tissue may lead to swelling and bruising of a user's skin as a
result of improving fascia tissue and health. After such a
treatment, lotion composition described herein may be used to
tighten the skin and reduce muscle pain, bruising, and swelling,
and can significantly improve skin aesthetic appearance, such as
skin tightening, and would be useful in the formulation of
treatments and products for the skin. As described herein, novel
and beneficial compositions for the treatment of muscle pain,
bruising, skin aesthetic appearance, swelling and the like, are
provided along with methods for forming such compositions. The
cream may be used anytime regardless of time of application and
with or without complimentary other compositions.
[0008] One aspect of the present disclosure is the provision of
compositions for reducing muscle pain, bruising, swelling, and
loose skin following treatment with or without a fascia therapy
device. In one embodiment, the composition includes water. In
another embodiment, the composition includes Aloe barbadensis leaf
juice. In yet another embodiment, the composition includes SD
Alcohol 40-B. In still another embodiment, the composition includes
cetearyl alcohol. In other embodiments, the composition includes
glyceryl stearate SE. In yet other embodiments, the composition
includes isopropyl myristate. In still other embodiments, the
composition includes caprylic/capric triglyceride. In some
embodiments, the composition includes propylene glycol. In
particular embodiments, the composition includes glycerin. In
certain embodiments, the composition includes Ceteareth-20. In one
embodiment, the composition includes Arnica montana flower extract.
In another embodiment, the composition includes oat kernel extract.
In one embodiment, the oat kernel extract is from Avena sativa. In
yet another embodiment, the composition includes tocopheryl
acetate. In still another embodiment, the composition includes
ammonium acryloyldimethyltaurate/VP copolymer. In other
embodiments, the composition includes disodium EDTA. In yet other
embodiments, the composition includes phenoxyethanol. In still
other embodiments, the composition includes caprylyl glycol. In
some embodiments, the composition includes ethylexylglycerin. In
particular embodiments, the composition includes hexylene glycol.
In certain embodiments, the composition includes fragrance. In one
embodiment, the composition includes citric acid.
[0009] In some embodiments, the water is from about 55%, about 56%,
about 57%, about 58%, about 59%, about 60%, about 61%, about 62%,
about 63%, about 64%, about 65%, about 66%, about 67%, about 68%,
about 69%, about 70%, about 71%, about 72%, about 73%, about 74%,
about 75%, about 76%, about 77%, about 78%, about 79%, about 80%,
about 81%, about 82%, about 83%, about 84%, or about 85% of the
total weight by volume of the composition. In another embodiment,
the Aloe barbadensis leaf juice is from about 5.0%, about 5.5%,
about 6.0%, about 6.5%, about 7.0%, about 7.5%, about 8.0%, about
8.5%, about 9.0%, about 9.5%, or about 10.0% of the total weight by
volume of the composition. In yet another embodiment, the SD
Alcohol 40-B is from about 1.0%, about 1.5%, about 2.0%, about
2.5%, about 3.0%, about 3.5%, or about 4.0% of the total weight by
volume of the composition. In still another embodiment, the
cetearyl alcohol is from about 1.0%, about 1.5%, about 2.0%, about
2.5%, about 3.0%, about 3.5%, or about 4.0% of the total weight by
volume of the composition. In other embodiments, the glyceryl
stearate SE is from about 1.0%, about 1.5%, about 2.0%, about 2.5%,
about 3.0%, about 3.5%, or about 4.0% of the total weight by volume
of the composition. In yet other embodiments, the isopropyl
myristate is from about 1.0%, about 1.5%, about 2.0%, about 2.5%,
about 3.0%, about 3.5%, or about 4.0% of the total weight by volume
of the composition. In still other embodiments, the caprylic/capric
triglyceride is from about 1.0%, about 1.5%, about 2.0%, about
2.5%, about 3.0%, about 3.5%, or about 4.0% of the total weight by
volume of the composition. In some embodiments, the propylene
glycol is from about 1.0%, about 1.5%, about 2.0%, about 2.5%,
about 3.0%, about 3.5%, or about 4.0% of the total weight by volume
of the composition. In particular embodiments, the glycerin is from
about 1.0%, about 1.5%, about 2.0%, about 2.5%, about 3.0%, about
3.5%, or about 4.0% of the total weight by volume of the
composition. In certain embodiments, the Ceteareth-20 is from about
1.0%, about 1.5%, about 2.0%, about 2.5%, about 3.0%, about 3.5%,
or about 4.0% of the total weight by volume of the composition. In
one embodiment, the Arnica montana flower extract is from about
0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%,
about 0.7%, about 0.8%, or about 0.9% of the total weight by volume
of the composition. In another embodiment, the oat kernel extract
is from about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%,
about 0.6%, about 0.7%, about 0.8%, or about 0.9% of the total
weight by volume of the composition. In yet another embodiment, the
tocopheryl acetate is from about 0.1%, about 0.2%, about 0.3%,
about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, or
about 0.9% of the total weight by volume of the composition. In
still another embodiment, the ammonium acryloyldimethyltaurate/VP
copolymer is from about 0.1%, about 0.2%, about 0.3%, about 0.4%,
about 0.5%, about 0.6%, about 0.7%, about 0.8%, or about 0.9% of
the total weight by volume of the composition. In other
embodiments, the disodium EDTA is from about 0.01%, about 0.02%,
about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%,
about 0.08%, or about 0.09% of the total weight by volume of the
composition. In yet other embodiments, the phenoxyethanol is from
about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about
0.6%, about 0.7%, about 0.8%, or about 0.9% of the total weight or
volume of the composition. In still other embodiments, the caprylyl
glycol is from about 0.1%, about 0.2%, about 0.3%, about 0.4%,
about 0.5%, about 0.6%, about 0.7%, about 0.8%, or about 0.9% of
the total weight by volume of the composition. In some embodiments,
the ethylexylglycerin is from about 0.01%, about 0.02%, about
0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about
0.08%, or about 0.09% of the total weight by volume of the
composition. In particular embodiments, the hexylene glycol is from
about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%,
about 0.06%, about 0.07%, about 0.08%, or about 0.09% of the total
weight by volume of the composition. In certain embodiments, the
fragrance is from about 0.01%, about 0.02%, about 0.03%, about
0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, or about
0.09% of the total weight by volume of the composition. In one
embodiment, the citric acid is from about 0.01%, about 0.02%, about
0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about
0.08%, or about 0.09% of the total weight by volume of the
composition.
[0010] 100091 In some embodiments, the composition can be stored in
a dispenser. In one embodiment, the dispenser can be integrated
into or onto the fascia therapy device. In an alternative
embodiment, the dispenser can include a member that functions to
dispense the composition in a roll-on, sponge applicator, or other
dispensing technique. A cartridge that includes the composition can
be used and positioned within a dispensing mechanism of the fascia
therapy device. In particular embodiments, the composition can be
applied from a dispenser. The cream can be dispersed in unlimited
ways.
[0011] Another aspect of the present disclosure is the provision of
a method of forming a composition for tightening the skin and
reducing muscle pain, bruising, swelling to significantly improve
skin aesthetic appearance while lubricating skin after treatment
with a fascia therapy device or any other time, whether or not a
fascia treatment is performed. In one embodiment, the method
comprises mixing water, Aloe barbadensis leaf juice, SD Alcohol
40-B, cetearyl alcohol, glyceryl stearate SE, isopropyl myristate,
caprylic/capric triglyceride, propylene glycol, glycerin,
Ceteareth-20, Arnica montana flower extract, oat kernel extract,
tocopheryl acetate, ammonium acryloyldimethyltaurate/VP copolymer,
disodium EDTA, phenoxyethanol, caprylyl glycol, ethylexylglycerin,
hexylene glycol, fragrance, citric acid, or any combination
thereof.
DETAILED DESCRIPTION OF THE INVENTION
[0012] A combination of ingredients, with a surprisingly pleasant
aroma, have been found to synergistically reduce loose skin, muscle
pain, bruising, and swelling over a period of time, following
treatment with a fascia therapy device or any other time. Treatment
with a fascia therapy device can produce better results of certain
conditions, such as reducing subcutaneous fat, improving blood
flow, and many other conditions. A fascia tissue treatment device,
as described in U.S. Patent Application No. 2014/0243718, can
include a bar and a plurality of flower-like or claw-shaped
element(s) connected to the bar along a plane. The flower-like
elements can each include multiple fingers that are stiff and
extend outward from the bar. Without being bound by theory, it is
believed that at least one of the ingredients in the oil or lotion
described herein work to suppress inflammatory processes in the
body for muscle pain, bruising, and swelling reducing effects
following application and use of the fascia tissue treatment
device. The oil or lotion described herein may also be used as a
standalone solution to suppress inflammatory processes and so
forth. In particular, the oil or lotion composition may mitigate
subcutaneous inflammatory processes, thereby reducing muscle pain,
bruising, and swelling while suppressing the uniquely unpleasant
odor typical of arnica flower extract. A dermatologically
acceptable vehicle was discovered that provides a stable
environment for the active ingredients, and a pleasant scent and
tactile property may be provided when applied to skin. Because the
cream provides for the pleasant scent, a common resistance of users
of certain ingredients may be reduced or eliminated.
[0013] The principles described herein relate to compositions for
reducing muscle pain, bruising, swelling, and loose skin having a
pleasant odor, for application to skin post-treatment of a fascia
tissue treatment device or any other time. In one embodiment, the
composition includes the active ingredients Arnica montana flower
extract, caprylic/capric triglyceride, and tocopherol. In
particular embodiments, to provide a satisfying and pleasant aroma
in addition to adequate soothing relief post-treatment with a
fascia tissue treatment device, the composition includes additional
compounds in conjunction with active ingredients. In some
embodiments, the composition includes water, Aloe barbadensis leaf
juice, SD Alcohol 40-B, cetearyl alcohol, glyceryl stearate SE,
isopropyl myristate, caprylic/capric triglyceride, propylene
glycol, glycerin, Ceteareth-20, Arnica montana flower extract, oat
kernel extract, tocopheryl acetate, ammonium
acryloyldimethyltaurate/VP copolymer, disodium EDTA,
phenoxyethanol, caprylyl glycol, ethylexylglycerin, hexylene
glycol, fragrance, citric acid, or any combination thereof. The
compositions can include any number of combinations of additional
ingredients described throughout this specification. The
concentrations of the any ingredient within the compositions can
vary. In non-limiting embodiments, for example, the compositions
can comprise, consisting essentially of, or consist of, in their
final form, for example, about 0.01% to about 85.00% or any range
derivable therein, of at least one of the ingredients that are
described throughout the specification and claims. The percentage
can be calculated by weight of the total composition. Comparable
percentages may be provided for by volume of the total composition.
A person of ordinary skill in the art would understand that the
concentrations can vary depending on the addition, substitution,
and/or subtraction of ingredients in a given composition.
[0014] The disclosed compositions can also include various
antioxidants to retard oxidation of one or more components.
Additionally, the prevention of the action of microorganisms can be
brought about by preservatives, such as various antibacterial and
antifungal agents. Further, the disclosed compositions can also
include cosmetic ingredients, UV absorption agents, moisturizing
agents, structuring agents, emulsifiers, thickening agents, and
pharmaceutical ingredients.
[0015] The disclosed compositions can be incorporated into all
types of formulations. Non-limiting examples of suitable
formulations include emulsions (e.g., water-in-oil,
water-in-oil-in-water, oil-in-water, silicone-in-water,
water-in-silicone, oil-in-water-in-oil, oil-in-water-in-silicone
emulsions), creams, lotions, solutions (both aqueous and
hydro-alcoholic), anhydrous bases (such as lipsticks and powders),
gels, and ointments or by other method or any combination of the
forgoing as would be known to one of ordinary skill in the art.
Variations and other appropriate formulations will be apparent to
the skilled artisan and are appropriate for use in the present
invention. In certain embodiments, the concentrations and
combinations of the compounds, ingredients, and agents may be
selected in such a way that the combinations are chemically
compatible and do not form complexes that precipitate from the
finished product.
[0016] It is also contemplated that ingredients identified
throughout this specification, including but not limited to Arnica
montana flower extract, caprylic/capric triglyceride, and
tocopherol, or any combinations thereof, can be individually or
combinatorially encapsulated for delivery to a target area, such as
skin. Non-limiting examples of encapsulation techniques include the
use of liposomes, vesicles, and/or nanoparticles (e.g.,
biodegradable and non-biodegradable colloidal particles comprising
polymeric materials in which the ingredient is trapped,
encapsulated, and/or absorbed) that can be used as delivery
vehicles to deliver the ingredient to skin. See, e.g., U.S. Pat.
Nos. 6,387,398; 6,203,802; and 5,411,744.
[0017] The principles described herein also relate to a process of
forming a composition to reduce muscle pain, bruising, swelling,
and loose skin while both lubricating the skin for application of a
fascia therapy device and having a pleasant odor and mitigating the
unpleasant odor of the active ingredients. In certain embodiments,
the process includes mixing water, Aloe barbadensis leaf juice, SD
Alcohol 40-B, cetearyl alcohol, glyceryl stearate SE, isopropyl
myristate, caprylic/capric triglyceride, propylene glycol,
glycerin, Ceteareth-20, Arnica montana flower extract, oat kernel
extract, tocopheryl acetate, ammonium acryloyldimethyltaurate/VP
copolymer, disodium EDTA, phenoxyethanol, caprylyl glycol,
ethylexylglycerin, hexylene glycol, fragrance, citric acid, or any
combination thereof.
[0018] Definitions and methods described herein are provided to
better define the present disclosure and to guide those of ordinary
skill in the art in the practice of the present disclosure. Unless
otherwise noted, terms are to be understood according to
conventional usage by those of ordinary skill in the relevant
art.
[0019] In some embodiments, numbers expressing quantities of
ingredients, properties such as molecular weight, reaction
conditions, and so forth, used to describe and claim certain
embodiments of the present disclosure are to be understood as being
modified in some instances by the term "about." In some
embodiments, the term "about" is used to indicate that a value
includes the standard deviation of the mean for the device or
method being employed to determine the value. In some embodiments,
the numerical parameters set forth in the written description and
attached claims are approximations that can vary depending upon the
desired properties sought to be obtained by a particular
embodiment. In some embodiments, the numerical parameters should be
construed in light of the number of reported significant digits and
by applying ordinary rounding techniques. Notwithstanding that the
numerical ranges and parameters setting forth the broad scope of
some embodiments of the present disclosure are approximations, the
numerical values set forth in the specific examples are reported as
precisely as practicable. The numerical values presented in some
embodiments of the present disclosure may contain certain errors
necessarily resulting from the standard deviation found in their
respective testing measurements. The recitation of ranges of values
herein is merely intended to serve as a shorthand method of
referring individually to each separate value falling within the
range. Unless otherwise indicated herein, each individual value is
incorporated into the specification as if it were individually
recited herein.
[0020] In some embodiments, the terms "a" and "an" and "the" and
similar references used in the context of describing a particular
embodiment (especially in the context of certain of the following
claims) can be construed to cover both the singular and the plural,
unless specifically noted otherwise. In some embodiments, the term
"or" as used herein, including the claims, is used to mean "and/or"
unless explicitly indicated to refer to alternatives only or the
alternatives are mutually exclusive.
[0021] The terms "comprise," "have" and "include" are open-ended
linking verbs. Any forms or tenses of one or more of these verbs,
such as "comprises," "comprising," "has," "having," "includes" and
"including," are also open-ended. For example, any method that
"comprises," "has" or "includes" one or more steps is not limited
to possessing only those one or more steps and can also cover other
unlisted steps. Similarly, any composition or device that
"comprises," "has" or "includes" one or more features is not
limited to possessing only those one or more features and can cover
other unlisted features.
[0022] All methods described herein can be performed in any
suitable order unless otherwise indicated herein or otherwise
clearly contradicted by context. The use of any and all examples,
or exemplary language (e.g., "such as") provided with respect to
certain embodiments herein is intended merely to better illuminate
the present disclosure and does not pose a limitation on the scope
of the present disclosure otherwise claimed. No language in the
specification should be construed as indicating any non-claimed
element essential to the practice of the present disclosure.
[0023] Groupings of alternative elements or embodiments of the
present disclosure disclosed herein are not to be construed as
limitations. Each group member can be referred to and claimed
individually or in any combination with other members of the group
or other elements found herein. One or more members of a group can
be included in, or deleted from, a group for reasons of convenience
or patentability. When any such inclusion or deletion occurs, the
specification is herein deemed to contain the group as modified
thus fulfilling the written description of all Markush groups used
in the appended claims.
[0024] All publications, patents, patent applications, and other
references cited in this application are incorporated herein by
reference in their entirety for all purposes to the same extent as
if each individual publication, patent, patent application or other
reference was specifically and individually indicated to be
incorporated by reference in its entirety for all purposes.
Citation of a reference herein shall not be construed as an
admission that such is prior art to the present disclosure.
[0025] Having described the present disclosure in detail, it will
be apparent that modifications, variations, and equivalent
embodiments are possible without departing the scope of the present
disclosure defined in the appended claims. Furthermore, it should
be appreciated that all examples in the present disclosure are
provided as non-limiting examples.
EXAMPLES
[0026] The following non-limiting examples are provided to further
illustrate the present disclosure. It should be appreciated by
those of skill in the art that the techniques disclosed in the
examples that follow represent approaches that have been found to
function well in the practice of the present disclosure, and thus
can be considered to constitute examples of modes for its practice.
However, those of skill in the art should, in light of the present
disclosure, appreciate that many changes can be made in the
specific embodiments that are disclosed and still obtain a like or
similar result without departing from the spirit and scope of the
present disclosure.
Example 1
Compounds
[0027] Loose skin, muscle pain, bruising, and swelling can be
reduced using the active ingredient Arnica Montana flower extract
optionally post-treatment of a user with fascia tissue treatment
device. A composition comprising water, Aloe barbadensis leaf
juice, SD Alcohol 40-B, cetearyl alcohol, glyceryl stearate SE,
isopropyl myristate, caprylic/capric triglyceride, propylene
glycol, glycerin, Ceteareth-20, Arnica Montana flower extract, oat
kernel extract, tocopheryl acetate, ammonium
acryloyldimethyltaurate/VP copolymer, disodium EDTA,
phenoxyethanol, caprylyl glycol, ethylexylglycerin, hexylene
glycol, fragrance, and citric acid can visibly reduce the unsightly
effects of loose skin, muscle pain, bruising, and swelling
following repeated topical applications during and/or after use of
a fascia therapy device.
[0028] The composition can include:
TABLE-US-00001 INCI Name Percent (wt/vol %) water (Aqua) 55.0-85.0
Aloe barbadensis leaf juice 5.0-10.0 SD Alcohol 40-B 1.0-4.0
cetearyl alcohol 1.0-4.0 glyceryl stearate SE 1.0-4.0 isopropyl
myristate 1.0-4.0 caprylic/capric triglyceride 1.0-4.0 propylene
glycol 1.0-4.0 glycerin 1.0-4.0 Ceteareth-20 1.0-4.0 Arnica montana
flower extract 0.1-0.9 Avena sativa kernel extract 0.1-0.9
tocopheryl acetate 0.1-0.9 ammonium acryloyldimethyltaurate/VP
0.1-0.9 copolymer disodium EDTA 0.01-0.09 phenoxyethanol 0.1-0.9
caprylyl glycol 0.1-0.9 ethylexylglycerin 0.01-0.09 hexylene glycol
0.01-0.09 fragrance 0.01-0.09 citric acid 0.01-0.09 Total
100.00
Example 2
Compound Preparation
[0029] To prepare a dermatologically acceptable vehicle that
provides a chemically stable and cosmetically acceptable
environment for the ingredients capable of reducing loose skin,
muscle pain, bruising, swelling and lubricating the skin during an
optional usage or application of a fascia therapy device, Arnica
Montana flower extract can be mixed with water, Aloe barbadensis
leaf juice, SD Alcohol 40-B, cetearyl alcohol, glyceryl stearate
SE, isopropyl myristate, caprylic/capric triglyceride, propylene
glycol, glycerin, Ceteareth-20, oat kernel extract, tocopheryl
acetate, ammonium acryloyldimethyltaurate/VP copolymer, disodium
EDTA, phenoxyethanol, caprylyl glycol, ethylexylglycerin, hexylene
glycol, fragrance, and citric acid.
[0030] The amount of each ingredient can vary. For example, the
composition can include water from about 55.0% to about 85.0%; Aloe
barbadensis leaf juice from about 5.0% to about 10.0%; SD Alcohol
40-B from about 1.0% to about 4.0%; cetearyl alcohol from about
1.0% to about 4.0%; glyceryl stearate SE from about 1.0% to about
4.0%; isopropyl myristate from about 1.0% to about 4.0%;
caprylic/capric triglyceride from about 1.0% to about 4.0%;
propylene glycol from about 1.0% to about 4.0%; glycerin from about
1.0% to about 4.0%; Ceteareth-20 from about 1.0% to about 4.0%;
Arnica Montana flower extract from about 0.1% to about 0.9%; oat
kernel extract from about 0.1% to about 0.9%; tocopheryl acetate
from about 0.1% to about 0.9%; ammonium acryloyldimethyltaurate/VP
copolymer from about 0.1% to about 0.9%; disodium EDTA from about
0.01% to about 0.09%; phenoxyethanol from about 0.1% to about 0.9%;
caprylyl glycol from about 0.1% to about 0.9%; ethylexylglycerin
from about 0.01% to about 0.09%; hexylene glycol from about 0.01%
to about 0.09%; fragrance from about 0.01% to about 0.09%; and
citric acid from about 0.01% to about 0.09% of the total weight by
volume of the entire composition.
[0031] As various modifications could be made in the compositions
and methods herein described without departing from the scope of
the invention, it is intended that all matter contained in the
foregoing description shall be interpreted as illustrative rather
than limiting. The breadth and scope of the present invention
should not be limited by any of the above-described exemplary
embodiments, but should be defined only in accordance with the
following claims appended hereto and their equivalents. All patent
and non-patent documents cited in this specification are
incorporated herein by reference in their entireties.
* * * * *